Introduction
============

Sexually transmitted infections are among the most common communicable conditions and affect the health and lives of people worldwide. The World Health Organization (WHO) periodically generates estimates to gauge the global burden of four of the most common curable sexually transmitted infections: chlamydia (etiological agent: *Chlamydia trachomatis*), gonorrhoea (*Neisseria gonorrhoeae*), trichomoniasis (*Trichomonas vaginalis*) and syphilis (*Treponema pallidum*).[@R1]^--^[@R6] The estimates provide evidence for programme improvement, monitoring and evaluation.

These sexually transmitted infections cause acute urogenital conditions such as cervicitis, urethritis, vaginitis and genital ulceration, and some of the etiological agents also infect the rectum and pharynx. Chlamydia and gonorrhoea can cause serious short- and long-term complications, including pelvic inflammatory disease, ectopic pregnancy, infertility, chronic pelvic pain and arthritis, and they can be transmitted during pregnancy or delivery. Syphilis can cause neurological, cardiovascular and dermatological disease in adults, and stillbirth, neonatal death, premature delivery or severe disability in infants. All four infections are implicated in increasing the risk of human immunodeficiency virus (HIV) acquisition and transmission.[@R7] Moreover, people with sexually transmitted infections often experience stigma, stereotyping, vulnerability, shame and gender-based violence.[@R8]

In May 2016, the World Health Assembly adopted the *Global health sector strategy on sexually transmitted infections, 2016--2021*.[@R9] This strategy includes rapid scale-up of evidence-based interventions and services to end sexually transmitted infections as public health concerns by 2030. The strategy sets targets for reductions in gonorrhoea and syphilis incidence in adults and recommends the establishment of global baseline incidences of sexually transmitted infections by 2018. The primary objectives of this study were to estimate the 2016 global and regional prevalence and incidence of chlamydia, gonorrhoea, trichomoniasis and syphilis in adult women and men.

Methods
=======

Prevalence estimation
---------------------

### Chlamydia, gonorrhoea and trichomoniasis

We generated estimates for these three infections through systematic reviews using the same methods as for the 2012 estimates.[@R6]

We searched for articles published between 1 January 2009 and 29 July 2018 in PubMed® without language restrictions. We used PubMed Medical subject heading (MeSH) terms for individual country names combined with: "chlamydia"\[MeSH Terms\] OR "chlamydia"\[All Fields\], "gonorrhoea"\[All Fields\] OR "gonorrhea"\[MeSH Terms\] OR "gonorrhea"\[All Fields\], "trichomonas infections"\[MeSH Terms\] OR ("trichomonas"\[All Fields\] AND "infections"\[All Fields\]) OR "trichomonas infections"\[All Fields\] OR "trichomoniasis"\[All Fields\]). We also asked WHO regional sexually transmitted infection advisors and other leading experts in the field for additional published and unpublished data.

To be eligible, studies had to collect most specimens between 2009 and 2016 or be published in 2010 or later if specimen collection dates were not available. Other study inclusion criteria were: sample size of at least 100 individuals; general population (e.g. pregnant women, women at delivery, women attending family planning clinics, men and women selected for participation in demographic and health surveys); and use of an internationally recognized diagnostic test with demonstrated precision using urine, urethral, cervical or vaginal specimens.

To reduce bias in the estimation of general population prevalence, we excluded studies conducted among the following groups: patients seeking care for sexually transmitted infection or urogenital symptoms, women presenting at gynaecology or sexual health clinics with sexually transmitted infection related issues, studies restricted to women with abnormal Papanicolaou test results, remote or indigenous populations, recent immigrant or migrant populations, men who have sex with men and commercial sex workers.

Two investigators independently reviewed all identified studies to verify eligibility. When more than one publication reported on the same population, we retained the publication with the most detailed information. For each included study, we calculated prevalence as the number of individuals with a positive test result divided by the total number tested. We then standardized these values by applying adjustment factors for the accuracy of the laboratory diagnostic test, study location (rural versus urban) and the age of the study population. If the adjustments resulted in a negative value, we replaced the value with 0.1% when doing the meta-analysis. The methods and adjustment factors were identical to those used to generate the 2012 estimates.[@R6]

We obtained estimates for 10 geographical areas (referred to as estimation regions).[@R6] Estimates for high-income North America (Canada and United States of America), were based on the latest published United States estimates that used data from multiple sources.[@R10]^,^[@R11] For the other nine estimation regions, we calculated a summary prevalence estimate by meta-analysis if there were three or more data points.[@R12] There were sufficient data to generate an estimate for chlamydia in women in all regions, but not for gonorrhoea or trichomoniasis. For regions with insufficient data for gonorrhoea and trichomoniasis, we assumed that prevalence was a multiple of the prevalence of chlamydia. The infection specific multiples were based on those studies that met the 2016 inclusion criteria (available from the data repository).[@R13] For men, when there were insufficient data for meta-analysis, the prevalence of an infection was assumed to be proportional to the prevalence in women. The male-to-female ratios were infection-specific and were set at the same values as in 2012 estimates.[@R6]

To reflect the contribution of populations at higher risk of infection (e.g. men who have sex with men and commercial sex workers), who are likely to be under-represented in general population samples, we increased prevalence estimates by 10%, as in the 2012 estimates,[@R6] for each estimation region, apart from high-income North America.

We performed the meta-analyses using a Bayesian approach with a Markov Chain Monte Carlo algorithm implemented with the software BRrugs in R package (R foundation, Vienna, Austria).[@R14] For each infection, the software generated 10 000 samples from the posterior distribution for the expected mean prevalence in each estimation region based on the *β*-binomial model, and used these to calculate the 2.5 and 97.5 uncertainty percentiles.[@R15] We calculated global and regional prevalence estimates for each infection by weighting each of the 10 000 samples from estimation regions according to population size, using United Nations population data for women and men aged 15--49 years.[@R16] We present results by WHO region, 2016 World Bank income classification[@R17] and 2017 sustainable development goal (SDG) region.[@R18] All analyses were carried out using R statistical software (R foundation).

### Syphilis

We based syphilis estimates on the WHO's published 2016 maternal prevalence estimates.[@R19] These estimates were generated by using Spectrum-STI, a statistical trend-fitting model in the publicly available Spectrum suite of health policy planning tools[@R20] and country specific data from the global Spectrum-STI syphilis database (available from the corresponding author). As in the 2012 estimation,[@R6] we assumed that the prevalence of syphilis in all women 15--49 years of age in each country was the same as in pregnant women. We then increased the estimate by 10% to reflect the contribution of populations at higher risk. The men to women prevalence ratio of syphilis was set at 1.0 and assumed to have a uniform distribution ± 33% around this value, in agreement with data from a recent global meta-analysis of syphilis.[@R21]

We generated regional and global estimates by weighting the contribution of each country by the number of women and men aged 15--49 years. Regional and global 95% uncertainty intervals (UIs) were generated using the delta method;[@R22] uncertainties were assumed to be independent across countries.

Incidence estimation
--------------------

We calculated incidence estimates for each infection by dividing prevalence by the average duration of infection for all estimation regions except high-income North America where published estimates were used.[@R10]^,^[@R11] Estimates of the average duration of infection were those used in the 2012 estimation[@R6] and assumed to have a uniform distribution of ± 33.3% around the average duration. We calculated uncertainty in incidence for a given region, sex and infection at the national level using the delta method;[@R22] uncertainty in the prevalence estimate was multiplied by uncertainty in the estimated duration of infection. Regional and global uncertainty intervals were generated assuming uncertainties were independent across countries.

Results
=======

Data availability
-----------------

### Chlamydia, gonorrhoea and trichomoniasis

Of the 7244 articles screened, 112 studies met the inclusion criteria for one or more of the three infections ([Fig. 1](#F1){ref-type="fig"}). We identified an additional 18 studies through expert consultations and reviewing reference lists (Nguyen M et al., Hanoi Medical University, Viet Nam, personal communication, 23 March 2018; El Kettani A et al., National Institute of Hygiene, Morocco, personal communication, 2 May 2016; Galdavadze K et al., Disease Control and Public Health, Republic of Georgia; personal communication, 22 August 2017).[@R23]^--^[@R150] Of these 130 studies, 111 reported data for women only ([Table 1](#T1){ref-type="table"}; available at: <http://www.who.int/bulletin/volumes/96/8/18-228486>), three reported data for men only ([Table 2](#T2){ref-type="table"}; available at: <http://www.who.int/bulletin/volumes/96/8/18-228486>) and 16 reported data for both women and men ([Table 1](#T1){ref-type="table"} and [Table 2](#T2){ref-type="table"}). Only 34 studies in women and four studies in men provided information on all three infections. The included studies contained 100 data points in women for chlamydia, 64 for gonorrhoea and 69 for trichomoniasis. In men, there were 16 data points for chlamydia, 11 for gonorrhoea and seven for trichomoniasis ([Table 3](#T3){ref-type="table"}).

![Flowchart of the selection of studies for estimating the prevalence and incidence of chlamydia, gonorrhoea and trichomoniasis, 2016](BLT.18.228486-F1){#F1}

###### Included studies on chlamydia, gonorrhoea and trichomoniasis prevalence in women, 2009--2016

  Study, by WHO region                              Country or territory and location                             Date of study        Population and age, years                                           Chlamydia                                     Gonorrhoea      Trichomoniasis                                                                                                 
  ------------------------------------------------- ------------------------------------------------------------- -------------------- ------------------------------------------------------------------- ----------------------------------- --------- ------------ -- ------------------------------------------ -------- ------ -- ----------------------------------------- ------ ------
  **African Region**                                                                                                                                                                                                                                                                                                                                                                    
  Wynn et al., 2018[@R23]                           Botswana, Gaborone                                            Jul 2015--May 2016   ANC clinic attendees, \> 18                                         Genital fluid, amplification test   400       7.8             Genital fluid, amplification test          400      1.3       Genital fluid, amplification test         400    5.3
  Ginindza et al., 2017[@R43]                       Eswatini, national^b^                                         Jun--Jul 2015        Outpatient clinic attendees, 15--49                                 Genital fluid, amplification test   655       5.8             Genital fluid, amplification test          655      5.3       Genital fluid, amplification test         655    7.8
  Eshete et al., 2013[@R24]                         Ethiopia, Jimma Town                                          Dec 2011--May 2012   ANC clinic attendees, 15--36                                        NR                                  NR        NR              NR                                         NR       NR        Genital fluid, culture                    361    5.0
  Mulu et al., 2015[@R25]                           Ethiopia, Bahir Dar                                           May--Nov 2013        ANC clinic attendees, 15--49                                        NR                                  NR        NR              Genital fluid, culture and Gram stain^a^   214      0.9       Genital fluid, microscopy                 214    1.4
  Schönfeld et al., 2018[@R26]                      Ethiopia, Asella                                              May 2014--Sep 2015   ANC clinic attendees, adults                                        NR                                  NR        NR              NR                                         NR       NR        Genital fluid, point-of-care test^b^      580    5.3
  Volker et al., 2017[@R27]                         Ghana, Western region                                         Oct 2011--Jan 2012   Attendees at a hospital maternity clinic, 14--48                    Genital fluid, amplification test   177       1.7             Genital fluid, culture                     180      0.0       NR                                        NR     NR
  Jespers et al., 2014[@R28]                        Kenya, Mombasa                                                2010--2011           Participants in a community survey, 18--35                          Genital fluid, amplification test   110       3.6             Genital fluid, amplification test          110      0.9       Genital fluid, culture                    110    2.7
  Kinuthia et al., 2015[@R29]                       Kenya, Ahero and Bondo districts                              May 2011--Jun 2013   ANC clinic attendees, ≥ 14                                          Genital fluid, amplification test   1276      5.5             Genital fluid, amplification test          1276     2.5       Genital fluid, microscopy                 1278   6.3
  Drake et al., 2013[@R30]                          Kenya, Western Kenya                                          Pre-2013             ANC clinic attendees, 14--21                                        Genital fluid, amplification test   537       4.7             Genital fluid, amplification test          537      1.7       Genital fluid, microscopy                 537    5.6
  Masese et al., 2017[@R31]                         Kenya, Mombasa                                                Aug 2014--Mar 2015   Students, 15--24                                                    Urine, amplification test           451       3.5             Urine, amplification test                  451      1.6       Urine, amplification test                 451    0.7
  Masha et al., 2017[@R32]                          Kenya, Kilifi                                                 Jul--Sep 2015        ANC clinic attendees, 18--45                                        Urine, amplification test           202       14.9            Urine, amplification test                  202      1.0       Genital fluid, culture                    202    7.4
  Nkhoma et al., 2017[@R33]                         Malawi, Mangochi District                                     Feb 2011--Aug 2012   ANC clinic attendees, ≥ 15                                          NR                                  NR        NR              NR                                         NR       NR        Genital fluid, microscopy                 1210   10.5
  Olowe et al., 2014[@R34]                          Nigeria, Osogba                                               Jul--Apr 2012        ANC clinic attendees, adults                                        NR                                  NR        NR              NR                                         NR       NR        Genital fluid, microscopy                 100    2.0
  Etuketu et al., 2015[@R35]                        Nigeria, Abeokutu                                             Jun--Jul 2013        ANC clinic attendees, 15--44                                        NR                                  NR        NR              NR                                         NR       NR        Genital fluid, microscopy                 300    10.3
  Muvunyi et al., 2011[@R36]                        Rwanda, Kigali                                                Nov 2007--Mar 2010   Controls for infertility study, adults                              Genital fluid, amplification test   312       3.8             NR                                         NR       NR        NR                                        NR     NR
  Franceschi et al., 2016[@R37]                     Rwanda, Kigali                                                Apr 2013--May 2014   Students, 18--20                                                    Urine, amplification test           912       2.2             NR                                         NR       NR        NR                                        NR     NR
  Vieira-Baptista et al., 2017[@R38]                Sao Tome and Principe, Principe                               2015                 Attendees at a primary health-care clinic, 21--60                   Genital fluid, amplification test   100       3.0             Genital fluid, amplification test          100      2.0       Genital fluid, amplification test         100    8.0
  Moodley et al., 2015[@R39]                        South Africa, Durban                                          May 2008--Jun 2010   ANC clinic attendees, adults                                        Genital fluid, amplification test   1459      17.8            Genital fluid, amplification test          1459     6.4       Genital fluid, amplification test         1459   15.3
  Jespers et al., 2014[@R28]                        South Africa, Johannesburg                                    2010--2011           ANC clinic attendees, adults                                        Genital fluid, amplification test   109       16.5            Genital fluid, amplification test          109      0.9       Genital fluid, culture                    109    4.6
  Peters et al., 2014[@R40]                         South Africa, Mopani District                                 Nov 2011--Feb 2012   Attendees at a primary health-care clinic, 18--49                   Genital fluid, amplification test   603       16.1            Genital, amplification test                603      10.1      NR                                        NR     NR
  de Waaij et al., 2017[@R41]                       South Africa, Mopani District                                 Nov 2011--Feb 2012   Attendees at a primary health-care clinic, 18--49                   NR                                  NR        NR              NR                                         NR       NR        Genital fluid, amplification test         575    19.7
  Francis et al., 2018[@R42]                        South Africa, KwaZulu-Natal                                   Oct 2016--Jan 2017   Youth people, 15--24                                                Genital, amplification test         259       11.2            Genital fluid, amplification test          259      1.9       Genital fluid, amplification test         259    4.6
  Tchelougou et al., 2013[@R44]                     Togo, Sokodé                                                  Jun 2010--Aug 2011   ANC clinic attendees, adults                                        NR                                  NR        NR              NR                                         NR       NR        Genital fluid, microscopy                 302    3.6
  Donders et al., 2016[@R45]                        Uganda, Kampala                                               Pre-2015             Outpatient clinic attendees, adult                                  Genital fluid, amplification test   360       1.4             Genital fluid, amplification test          360      1.7       Genital fluid, amplification test         360    6.7
  Rutherford et al., 2014[@R46]                     Uganda, Kampala                                               Sep 2008--Apr 2009   Students, 19--25                                                    Genital fluid, amplification test   280       2.5             Genital fluid, amplification test          280      1.1       Genital fluid, culture                    247    0.8
  de Walque et al., 2012[@R47]                      United Republic of Tanzania, Kilombero and Ulanga Districts   Feb--Apr 2009        Participants in HIV prevention trial, 18--30                        Genital fluid, amplification test   1204      2.7             Genital fluid, amplification test          1204     1.4       Genital fluid, amplification test         1204   16.2
  Chiduo et al., 2012[@R48]                         United Republic of Tanzania, Tanga                            May 2009--Oct 2010   ANC clinic attendees, 18--44                                        Genital fluid, amplification test   185       1.6             Genital fluid, culture and Gram stain      185      1.6       Genital fluid, microscopy                 185    11.4
  Hokororo et al., 2015[@R49]                       United Republic of Tanzania, Mwanza                           Apr--Dec 2012        ANC clinic attendees, 14--20                                        Urine, amplification test           403       11.4            Urine, amplification test                  403      6.7       Genital fluid, microscopy                 403    13.4
  Lazenby et al., 2014[@R50]                        United Republic of Tanzania, Arusha District                  Pre-2014             Participants for cervical cancer screening, 30--60                  Genital fluid, amplification test   324       0.0             Genital fluid, amplification test          324      0.0       Genital fluid, amplification test         297    10.4
  Maufi et al., 2018[@R51]                          United Republic of Tanzania, Mwanza                           Nov 2014--Apr 2015   ANC clinic attendees, 17--46                                        NR                                  NR        NR              NR                                         NR       NR        Genital fluid, microscopy                 365    10.4
  Chaponda et al., 2016[@R52]                       Zambia, Nchelenge District                                    Nov 2013--Apr 2014   ANC clinic attendees, adults                                        Genital fluid, amplification test   1083      5.2             Genital fluid, amplification test          1083     3.1       Genital fluid, amplification test         1083   24.8
  Stephen et al., 2017[@R53]                        Zimbabwe, Harare                                              Jan 2012--Apr 2012   ANC clinic attendees, \> 18                                         Genital fluid, amplification test   242       5.8             NR                                         NR       NR        NR                                        NR     NR
  **Region of the Americas**                                                                                                                                                                                                                                                                                                                                                            
  Touzon et al., 2014[@R54]                         Argentina, Buenos Aires                                       Jan 2010--Dec 2012   ANC clinic attendees, adults                                        NR                                  NR        NR              NR                                         NR       NR        Genital fluid, culture                    1238   1.8
  Testardini et al., 2016[@R55]                     Argentina, Buenos Aires                                       Apr 2010--Aug 2011   ANC clinic attendees, adults                                        NR                                  NR        NR              NR                                         NR       NR        Genital fluid, amplification test         386    5.2
  Mucci et al., 2016[@R56]                          Argentina, Buenos Aires                                       Aug 2012--Jan 2013   ANC clinic attendees, 10--42                                        NR                                  NR        NR              Genital fluid, culture                     210      0.5       Genital fluid, microscopy                 210    1.4
  Department of Public Health 2018[@R57]            Bahamas, national                                             2016                 ANC clinic attendees, adults                                        Urine, amplification test           2504      12.0            Urine, amplification test                  2504     2.0       NR                                        NR     NR
  Magalhaes et al., 2015[@R58]                      Brazil, Rio Grande do Norte State                             2008--2012           Participants for cervical cancer screening, 25--60                  Genital fluid, amplification test   1134      10.9            NR                                         NR       NR        NR                                        NR     NR
  Miranda et al., 2014[@R59]                        Brazil, national                                              Mar--Nov 2009        ANC clinic attendees, 15--24                                        NR                                  NR        NR              NR                                         NR       NR        Genital fluid, amplification test         299    7.7
  Pinto et al., 2011[@R60]                          Brazil, national                                              Mar--Nov 2009        ANC clinic attendees, 15--24                                        Urine, amplification test           2071      9.8             Urine, amplification test                  2071     1.0       NR                                        NR     NR
  Ferreira et al., 2015[@R61]                       Brazil, Belem and Para                                        2009--2011           ANC clinic attendees, \< 19                                         Genital fluid, amplification test   168       16.7            NR                                         NR       NR        Genital fluid, culture                    168    3.0
  Piazzetta et al., 2011[@R62]                      Brazil, Curitiba                                              Pre-2011             Sexually active youth people, 16--23                                Urine, amplification test           335       10.7            Urine, amplification test                  335      1.5       NR                                        NR     NR
  Silveira MF et al., 2017[@R63]                    Brazil, Pelotas                                               Dec 2011--May 2013   Attendees at a hospital maternity clinic, 18--24                    Genital fluid, amplification test   562       12.3            NR                                         NR       NR        NR                                        NR     NR
  Mesenburg et al., 2013[@R64]                      Brazil, Pelotas                                               Dec 2011--Jan 2013   ANC clinic attendees, \< 30                                         Genital fluid, amplification test   361       15.0            NR                                         NR       NR        NR                                        NR     NR
  Gatti et al., 2017[@R65]                          Brazil, Rio Grande                                            Jan 2012--Jan 2015   ANC clinic attendees, adults                                        NR                                  NR        NR              NR                                         NR       NR        Genital fluid, amplification test         204    5.9
  Marconi et al., 2015[@R66]                        Brazil, Botucatu                                              Sep 2012--Jan 2013   Participants for cervical cancer screening, 14--54                  NR                                  NR        NR              NR                                         NR       NR        Genital fluid, microscopy                 1519   1.4
  Neves et al., 2016[@R67]                          Brazil, Manaus                                                Oct 2012--Dec 2013   Attendees at a primary health-care clinic, 14--25                   Genital fluid, amplification test   1169      13.1            NR                                         NR       NR        NR                                        NR     NR
  Zamboni et al., 2016[@R68]                        Brazil, Santiago                                              Mar 2013--Mar 2014   Outpatient clinic attendees, 15--24                                 Genital fluid, amplification test   181       5.5             NR                                         NR       NR        NR                                        NR     NR
  Melo et al., 2016[@R69]                           Brazil, Region of La Araucanía                                2013--2014           Participants for cervical cancer screening, 18--24                  Genital fluid, amplification test   151       11.3            NR                                         NR       NR        NR                                        NR     NR
  Glehn et al., 2016[@R70]                          Brazil, Federal District                                      Nov 2014--Mar 2015   Attendees at a primary health-care clinic, 18--49                   NR                                  NR        NR              NR                                         NR       NR        Genital fluid, culture                    193    15.5
  Ovalle et al., 2012[@R71]                         Chile, Santiago                                               Apr 2010--Oct 2010   ANC clinic attendees, adults                                        Genital fluid, amplification test   255       5.9             Genital fluid, culture                     255      0.0       Genital fluid, culture                    255    2.4
  Huneeus et al., 2018[@R72]                        Chile, Santiago                                               2012--2014           Sexually active youth people, \< 25                                 Genital fluid, amplification test   171       8.8             Genital fluid, amplification test          171      0.6       Genital fluid, amplification test         171    0.0
  Villaseca et al., 2015[@R73]                      Chile, Santiago                                               Jun 2013--Dec 2013   Attendees at a family health clinic, 15--54                         NR                                  NR        NR              NR                                         NR       NR        Genital fluid, amplification test         101    3.0
  Stella et al., 2011[@R74]                         Colombia, rural Medellin                                      2009--2010           Students, 15--18                                                    NR                                  NR        NR              Genital fluid, culture                     262      0.0       NR                                        NR     NR
  Paredes et al., 2015[@R75]                        Colombia, Sabana Centro province                              2011                 Students, 14--19                                                    Urine, amplification test           436       3.2             Urine, amplification test                  436      0.2       NR                                        NR     NR
  Giraldo-Ospina et al., 2015[@R76]                 Colombia, Dosquebradas                                        Jun 2012--Aug 2013   ANC clinic attendees, 15--47                                        Genital fluid, amplification test   101       0.0             Genital fluid, culture                     101      2.0       NR                                        NR     NR
  Ceron et al., 2014[@R77]                          Colombia, Bogota                                              Aug--Dec. 2013       ANC clinic attendees, 15--40                                        Genital fluid, amplification test   226       5.3             Genital fluid, amplification test          226      0.0       NR                                        NR     NR
  Jobe et al., 2014[@R78]                           Haiti, Jérémie                                                Oct 2012             Attendees at a primary health-care clinic, 16--75                   Genital fluid, amplification test   199       11.6            Genital fluid, amplification test          199      4.0       Genital fluid, amplification test         199    19.6
  Jobe et al., 2014[@R78]                           Haiti, Jérémie                                                Oct 2012             Attendees at a primary health-care clinic, 19--78                   Genital fluid, amplification test   104       1.9             Genital fluid, amplification test          104      1.0       Genital fluid, amplification test         104    13.5
  Scheildell et al., 2018[@R79]                     Haiti, Gressier                                               Aug--Oct 2013        ANC clinic attendees, adults                                        Urine, amplification test           200       8.0             Urine, amplification test                  200      3.0       Urine, amplification test                 200    20.5
  Bristow et al., 2017[@R80]                        Haiti, Port-au-Prince                                         Oct 2015--Jan 2016   ANC clinic attendees, \> 18                                         Genital fluid, amplification test   300       14.0            Genital fluid, amplification test          300      2.7       Genital fluid, amplification test         300    27.7
  Conde-Ferráez et al., 2017[@R81]                  Mexico, Merida                                                Aug 2010--Jan 2011   ANC clinic attendees, adults                                        Genital fluid, amplification test   121       8.3             NR                                         NR       NR        NR                                        NR     NR
  López-Monteon et al., 2013[@R82]                  Mexico, central Veracruz                                      Jun--Jul 2012        Attendees at a primary health-care clinic, 14--50                   NR                                  NR        NR              NR                                         NR       NR        Urine, amplification test                 158    19.0
  Magana-Contreras et al., 2015[@R83]               Mexico, Villahermosa                                          Jan 2013--Nov 2014   Participants for cervical cancer screening, 16--74                  Genital fluid, amplification test   201       1.5             NR                                         NR       NR        NR                                        NR     NR
  Casillas-Vega et al., 2017[@R84]                  Mexico, Jalisco                                               Sep 2013--Aug 2014   ANC clinic attendees, adults                                        Genital fluid, amplification test   287       10.8            NR                                         NR       NR        NR                                        NR     NR
  Cabeza et al., 2015[@R85]                         Peru, Lima                                                    Dec 2012--Jan 2013   ANC clinic attendees, ≥ 16                                          Genital fluid, amplification test   600       10.0            NR                                         NR       NR        NR                                        NR     NR
  van der Helm et al., 2013[@R86]                   Suriname, Paramaribo                                          Mar 2008--Jul 2010   Attendees at a family planning clinic, adults                       Genital fluid, amplification test   819       9.5             NR                                         NR       NR        NR                                        NR     NR
  van der Helm et al., 2012[@R87]                   Suriname, Paramaribo                                          Jul 2009--Feb 2010   Attendees at a family planning clinic, \> 18                        Genital fluid, amplification test   753       9.2             NR                                         NR       NR        NR                                        NR     NR
  **South-East Asia Region**                                                                                                                                                                                                                                                                                                                                                            
  Franceschi et al., 2016[@R37]                     Bhutan, Thimpu and Paro                                       Sep 2013             Students in an HPV vaccination study, 18--20                        Urine, amplification test           973       3.4             NR                                         NR       NR        NR                                        NR     NR
  Vidwan et al., 2012[@R88]                         India, Vellore                                                Apr 2009--Jan 2010   ANC clinic attendees, 18--45                                        Genital fluid, amplification test   784       0.1             NR                                         NR       NR        NR                                        NR     NR
  Vijaya Mn et al., 2013[@R89]                      India, rural Bangalore                                        Oct 2010--Sep 2012   Attendees at an obstetrics and gynaecology clinic, 25--46           NR                                  NR        NR              NR                                         NR       NR        Genital fluid, culture                    750    2.1
  Kojima et al., 2018[@R90]                         India, Mysore district                                        May 2011--Jun 2014   ANC clinic attendees, young women                                   Genital fluid, amplification test   213       0.5             Genital fluid, amplification test          213      0.9       Genital fluid, amplification test         213    6.1
  Shah et al., 2014[@R91]                           India, Baroda                                                 May 2011--Aug 2012   ANC clinic attendees, 20--35                                        NR                                  NR        NR              NR                                         NR       NR        Genital fluid, microscopy                 233    3.4
  Krishnan et al., 2018[@R92]                       India, Udupi district                                         Aug 2013--May 2015   Community members, 18--65                                           Urine, amplification test           811       0.2             Urine, amplification test                  811      0.0       NR                                        NR     NR
  Ani & Darmayani 2017[@R93]                        Indonesia, Bali                                               Apr 2010             ANC clinic attendees, adults                                        NR                                  NR        NR              NR                                         NR       NR        Genital fluid, culture                    376    7.4
  Banneheke et al., 2013[@R94]                      Sri Lanka, Colombo district                                   2007--2009           Participants in diagnostic test study, 16--45                       NR                                  NR        NR              NR                                         NR       NR        Genital fluid, microscopy                 601    2.8
  **European Region**                                                                                                                                                                                                                                                                                                                                                                   
  Farr et al., 2016[@R95]                           Austria, Vienna                                               Jan 2005--Jan 2015   ANC clinic attendees, adults                                        NR                                  NR        NR              NR                                         NR       NR        Genital fluid, DNA probe-based assay^c^   3763   0.8
  Ljubin-Sternak et al., 2017[@R96]                 Croatia, Zagreb                                               Mar 2014--Feb 2015   Attendees at an obstetrics and gynaecology clinic, adults           Genital fluid, amplification test   8665      1.7             NR                                         NR       NR        NR                                        NR     NR
  Peuchant et al., 2015[@R97]                       France, Bordeaux                                              Jan--Jun 2011        ANC clinic attendees, 18--44                                        Genital fluid, amplification test   1004      2.5             Genital fluid, amplification test          1004     0.0       NR                                        NR     NR
  Peuchant et al., 2015[@R97]                       France, Bordeaux                                              Sep 2012--Feb 2013   ANC clinic attendees, \< 25                                         Genital fluid, amplification test   112       7.1             Genital fluid, amplification test          112      1.8       NR                                        NR     NR
  Galdavadze et al., personal communication 2012    Georgia, Tbilisi                                              Jul 2011--Mar 2012   ANC clinic attendees, 14--44                                        Urine, amplification test           300       5.0             Urine, amplification test                  300      0.3       NR                                        NR     NR
  Ikonomidis et al., 2015[@R98]                     Greece, Thessaly state                                        Feb 2012--Nov 2015   Attendees at a urology and gynaecology clinic, adults               Genital fluid, amplification test   130       0.8             NR                                         NR       NR        NR                                        NR     NR
  O\'Higgins et al., 2017[@R99]                     Ireland, Dublin                                               Dec 2011--Dec 2013   ANC clinic attendees, 16--25                                        Genital fluid, amplification test   2687      4.9             NR                                         NR       NR        NR                                        NR     NR
  Hassan et al., 2016[@R100]                        Ireland, Dublin                                               Jul 2014--Jan 2015   Participants for cervical cancer screening, 25--40                  Genital fluid, amplification test   236       3.0             Genital fluid, amplification test          236      0.0       NR                                        NR     NR
  Bianchi et al., 2016[@R101]                       Italy, Milan                                                  Dec 2008--Dec 2012   HPV vaccinated young women, 18--23                                  Genital fluid, amplification test   591       4.9             NR                                         NR       NR        NR                                        NR     NR
  Seraceni et al., 2016[@R102]                      Italy, north-eastern                                          Jan 2009--Dec 2014   Participants for cervical cancer screening, adults                  Genital fluid, amplification test   921       0.0             NR                                         NR       NR        NR                                        NR     NR
  Panatto et al., 2015[@R103]                       Italy, Turin, Milan and Genoa                                 Jan--Jun 2010        Women attending gynaecologic routine check-ups, 16--26              Genital fluid, amplification test   566       5.8             NR                                         NR       NR        NR                                        NR     NR
  Foschi et al., 2016[@R104]                        Italy, Bologna                                                Jan 2011--May 2014   Attendees at an obstetrics and gynaecology clinic, routine, \> 14   Genital fluid, amplification test   3072      3.4             NR                                         NR       NR        NR                                        NR     NR
  Matteelli et al., 2016[@R105]                     Italy, Brescia                                                Nov 2012--Mar 2013   Sexually active students, ≥ 18                                      Urine, amplification test           1297      1.9             Urine, amplification test                  1297     0.0       NR                                        NR     NR
  Camporiondo et al., 2016[@R106]                   Italy, Rome                                                   Mar 2013             Healthy women attending screening, 34--60                           Genital fluid, amplification test   309       0.0             Genital fluid, amplification test          309      0.0       Genital fluid, amplification test         309    1.3
  Leli et al., 2016[@R107]                          Italy, Perugia                                                Jan--Oct 2015        Outpatient clinic attendees, adults                                 NR                                  NR        NR              NR                                         NR       NR        Genital fluid, amplification test         1487   1.3
  Gravningen et al., 2013[@R108]                    Norway, Finnmark                                              2009                 Sexually active students, 15--20                                    Urine, amplification test           607       6.8             NR                                         NR       NR        NR                                        NR     NR
  Silva et al., 2013[@R109]                         Portugal, Porto                                               Pre-2013             Students, 14--30                                                    Genital fluid, amplification test   432       6.9             NR                                         NR       NR        NR                                        NR     NR
  Babinská et al., 2017[@R110]                      Slovakia, eastern parts                                       2011                 Community members, adults                                           Urine, amplification test           511       3.5             NR                                         NR       NR        NR                                        NR     NR
  Fernández-Benítez et al., 2013[@R111]             Spain, Laviana and Asturias                                   Nov 2010--Dec 2011   Sexually active youth people, 15--24                                Urine, amplification test           277       4.0             NR                                         NR       NR        NR                                        NR     NR
  Pineiro et al., 2016[@R112]                       Spain, Basque Autonomous Community                            Jan 2011--Dec 2014   Attendees at a hospital maternity clinic, 14--54                    Urine, amplification test           11 687    1.0             Urine, amplification test                  11 687   0.0       NR                                        NR     NR
  Field et al., 2018[@R113]                         United Kingdom, national                                      Sep 2010--Aug 2012   Sexually active adults, 16--44                                      NR                                  NR        NR              NR                                         NR       NR        Urine, amplification test                 2559   0.3
  Sonnenberg et al., 2013[@R114]                    United Kingdom, national                                      Sep 2010--Aug 2012   Sexually active adults, 16--44                                      Urine, amplification test           2665      2.3             Urine, amplification test                  2665     0.1       NR                                        NR     NR
  **Eastern Mediterranean Region**                                                                                                                                                                                                                                                                                                                                                      
  Nada et al., 2015[@R115]                          Egypt, Cairo                                                  Jan--Nov 2014        Controls for infertility study, adult                               Genital fluid, amplification test   100       2.0             NR                                         NR       NR        NR                                        NR     NR
  Hassanzadeh et al., 2013[@R116]                   Iran (Islamic Republic of), Shiraz                            2009--2011           ANC clinic attendees, adults                                        NR                                  NR        NR              Genital fluid, amplification test          1100     1.2       NR                                        NR     NR
  Hamid et al., 2011[@R117]                         Iran (Islamic Republic of), Zanjan province                   Apr 2009             Attendees at an obstetrics and gynaecology clinic, 15--45           NR                                  NR        NR              Genital fluid, culture                     328      0.9       NR                                        NR     NR
  Nourian et al., 2013[@R118]                       Iran (Islamic Republic of), Zanjan                            Jul 2009--Jun 2010   ANC clinic attendees, adults                                        NR                                  NR        NR              NR                                         NR       NR        Genital fluid, culture                    1000   3.3
  Rasti et al., 2011[@R119]                         Iran (Islamic Republic of), Kashan                            Pre-2010             ANC clinic attendees, adults                                        NR                                  NR        NR              NR                                         NR       NR        Genital fluid, culture                    450    0.4
  Dehgan Marvast et al., 2017[@R120]                Iran (Islamic Republic of), Yazd                              May--Sep 2010        ANC clinic attendees, 16--39                                        Urine, amplification test           250       0.0             NR                                         NR       NR        NR                                        NR     NR
  Ahmadi et al., 2016[@R121]                        Iran (Islamic Republic of), Sanandaj                          Aug 2012--Jan 2013   Controls for spontaneous abortion study, 19--42                     Genital fluid, amplification test   109       11.9            NR                                         NR       NR        NR                                        NR     NR
  Arbabi et al., 2014[@R122]                        Iran (Islamic Republic of), Kashan                            Oct 2012--Aug 2013   Attendees at a public health unit, 16--60                           NR                                  NR        NR              NR                                         NR       NR        Genital fluid, culture                    970    2.3
  Hasanabad et al., 2013[@R123]                     Iran (Islamic Republic of), Sabzevar                          Pre-2013             ANC clinic attendees, adolescents                                   Urine, amplification test           399       12.3            Urine, amplification test                  399      1.3       NR                                        NR     NR
  Mousavi et al., 2014[@R124]                       Iran (Islamic Republic of), Sanandai                          Feb--May 2013        Controls for infertility study, 14--40                              Genital fluid, amplification test   104       5.8             NR                                         NR       NR        NR                                        NR     NR
  Nateghi Rostami et al., 2016[@R125]               Iran (Islamic Republic of), Qom                               May 2013--Apr 2014   Attendees at an obstetrics and gynaecology clinic, 18--50           Genital fluid, amplification test   518       7.1             NR                                         NR       NR        NR                                        NR     NR
  Marashi et al., 2014[@R126]                       Iran (Islamic Republic of), not specified                     Pre-2014             Controls for infertility study, 20--40                              Genital fluid, amplification test   200       6.5             NR                                         NR       NR        NR                                        NR     NR
  Joolayi et al., 2017[@R127]                       Iran (Islamic Republic of), Ahvaz                             Aug 2016--Jan 2017   Controls for infertility study, 18--49                              Genital fluid, amplification test   125       1.6             NR                                         NR       NR        NR                                        NR     NR
  El Kettani et al., personal communication, 2016   Morocco, Rabat, Salé, Agadir and Fes                          Oct 2011--Dec 2011   Attendees at a family planning clinic, 18--49                       Genital fluid, amplification test   537       3.0             Genital fluid, amplification test          537      0.4       Genital, culture                          537    5.6
  El Kettani et al., personal communication, 2016   Morocco, Rabat, Salé, Agadir and Fes                          Dec 2011--Jan 2012   ANC clinic attendees, 18--49                                        Genital fluid, amplification test   252       3.6             Genital fluid, amplification test          252      0.8       Genital fluid, culture                    252    5.2
  Kamel 2013[@R128]                                 Saudi Arabia, Jazan                                           Jul 2011--Jun 2012   Controls for infertility study, 18--40                              Genital fluid, culture              100       4.0             NR                                         NR       NR        NR                                        NR     NR
  **Western Pacific Region**                                                                                                                                                                                                                                                                                                                                                            
  Wen 2013[@R129]                                   China, Wuhu                                                   2010                 Sexually active adults, adults                                      NR                                  NR        NR              NR                                         NR       NR        Genital fluid, microscopy                 2010   6.6
  Lu et al., 2013[@R130]                            China, Shenzhen                                               2011--2012           Attendees at an obstetrics and gynaecology clinic, adults           Genital fluid, amplification test   7892      5.4             NR                                         NR       NR        NR                                        NR     NR
  Xia et al., 2015[@R131]                           China, east, 16 cities                                        Jan--Dec 2011        Attendees at an hospital maternity clinic, adults                   Genital fluid, culture              108 268   1.5             NR                                         NR       NR        NR                                        NR     NR
  Zhang et al., 2017[@R132]                         China, Shaanxi province                                       Jun 2012--Jan 2013   ANC clinic attendees, adults                                        Genital fluid, amplification test   500       3.4             NR                                         NR       NR        NR                                        NR     NR
  Zhang et al., 2017[@R133]                         China, Beijing                                                Mar--Oct 2014        Attendees at an obstetrics and gynaecology clinic, 20--70           Genital fluid, amplification test   953       2.2             Genital fluid, amplification test          953      0.0       Genital fluid, microscopy                 953    1.7
  Imai et al., 2015[@R134]                          Japan, Miyazaki                                               Oct 2011--Feb 2012   Students, \> 18                                                     Urine, amplification test           1183      3.7             NR                                         NR       NR        NR                                        NR     NR
  Suzuki et al., 2015[@R135]                        Japan, national                                               Oct 2013--Mar 2014   ANC clinic attendees, adults                                        Genital fluid, amplification test   250 571   2.3             NR                                         NR       NR        NR                                        NR     NR
  Ministry of Health 2017[@R136]                    Mongolia, national                                            2016                 ANC clinic attendees, adults                                        NR                                  NR        NR              Genital fluid, culture                     69 278   0.5       NR                                        NR     NR
  Corsenac et al., 2015[@R137]                      New Caledonia, national                                       Aug--Dec 2012        Attendees at a primary health-care clinic, 18--49                   Urine, amplification test           376       10.1            Urine, amplification test                  376      3.5       NR                                        NR     NR
  Unger et al., 2015[@R138]                         Papua New Guinea, Madang                                      Nov 2009--Aug 2012   ANC clinic attendees, ≥ 16                                          Genital fluid, amplification test   674       4.5             Genital fluid, amplification test          674      8.2       Genital fluid, amplification test         674    21.8
  Wangnapi et al., 2015[@R139]                      Papua New Guinea, Madang                                      Feb 2011--Apr 2012   ANC clinic attendees, 16--39                                        Genital fluid, amplification test   362       11.0            Genital fluid, amplification test          362      9.7       Genital fluid, amplification test         362    21.3
  Vallely et al., 2017[@R140]                       Papua New Guinea, four provinces                              Dec 2011--Jan 2015   ANC clinic attendees, 18--59                                        Genital fluid, amplification test   765       22.9            Genital fluid, amplification test          765      14.2      Genital fluid, amplification test         765    22.4
  Vallely et al., 2017[@R140]                       Papua New Guinea, four provinces                              Dec 2011--Jan 2015   Participants for cervical cancer screening, 18--59                  Genital fluid, amplification test   614       7.5             Genital fluid, amplification test          614      8.0       Genital fluid, amplification test         614    15.0
  Badman et al., 2016[@R141]                        Papua New Guinea, Milne Bay                                   Aug--Dec 2014        ANC clinic attendees, \> 18                                         Genital fluid, amplification test   125       20.0            Genital fluid, amplification test          125      11.2      Genital fluid, amplification test         125    37.6
  Hahn et al., 2014[@R142]                          Republic of Korea, Seoul                                      Mar 2010--Apr 2011   ANC clinic attendees, adults                                        Genital fluid, amplification test   455       2.2             Genital fluid, amplification test          455      0.4       Genital fluid, amplification test         455    0.0
  Choe et al., 2012[@R143]                          Republic of Korea, Seoul                                      Mar--Dec 2010        Attendees at a health examination clinic, 20--59                    Urine, amplification test           805       3.2             Urine, amplification test                  805      0.2       NR                                        NR     NR
  Kim et al., 2011[@R144]                           Republic of Korea, Uijeongbu                                  Jul--Dec 2010        Attendees at a check-up clinic, 20--60                              Genital fluid, amplification test   279       3.9             Genital fluid, amplification test          279      0.4       Genital fluid, amplification test         279    2.5
  Kim et al., 2014[@R145]                           Republic of Korea, Seoul                                      Jan--Oct 2012        Attendees at a health examination clinic, 25--81                    Genital fluid, amplification test   405       1.2             Genital fluid, amplification test          405      0.0       Genital fluid, amplification test         405    0.2
  Marks et al., 2015[@R146]                         Solomon Islands, Honiara                                      Aug 2014             Attendees at a primary health-care clinic, 16--49                   Genital fluid, amplification test   296       20.3            Genital fluid, amplification test          296      5.1       NR                                        NR     NR
  Ton Nu et al., 2015[@R147]                        Viet Nam, Hue                                                 Sep 2010--Jun 2012   Attendees at a family planning clinic, adults                       NR                                  NR        NR              NR                                         NR       NR        Genital fluid, microscopy                 534    0.7
  Nguyen et al., personal communication, 2017       Viet Nam, Hanoi                                               2016--2017           ANC clinic attendees, \> 18                                         Genital fluid, amplification test   490       6.9             Genital fluid, amplification test          490      0.0       Genital fluid, amplification test         490    0.8

ANC: antenatal care; DNA: deoxyribonucleic acid; HIV: human immunodeficiency virus; NR: not reported; WHO: World Health Organization.

^a^ Studies that reported using both culture and Gram stain were assumed to have the same sensitivity and specificity values as culture.

^b^ The study used an immunochromatographic capillary-flow enzyme immunoassay and we assumed a sensitivity of 50% and specificity of 99%.

^c^ The study used a nonamplified, nucleic acid probe-based test system and we assumed the same specific and sensitivity values as for a nucleic acid amplification test.

###### Included studies on chlamydia, gonorrhoea and trichomoniasis prevalence in men, 2009--2016

  Study, by WHO region                    Country or territory and location                             Date of study        Population and age, years                            Chlamydia                            Gonorrhoea      Trichomoniasis                                                                 
  --------------------------------------- ------------------------------------------------------------- -------------------- ---------------------------------------------------- ----------------------------- ------ ------------ -- --------------------------- ------ ----- -- --------------------------- ------ -----
  **African Region**                                                                                                                                                                                                                                                                                                  
  Francis et al., 2018[@R42]              South Africa, KwaZulu-Natal                                   Oct 2016--Jan 2017   Community members, 15--24                            Urine, amplification test     188    5.3             Urine, amplification test   188    1.6      Urine, amplification test   188    0.5
  Rutherford et al., 2014[@R46]           Uganda, Kampala                                               Sep 2008--Apr 2009   Students, 19--25                                     Urine, amplification test     360    0.8             Urine, amplification test   360    0.0      NR                          NR     NR
  de Walque et al., 2012[@R47]            United Republic of Tanzania, Kilombero and Ulanga districts   Feb--April 2009      Participants in HIV prevention trial, 18--30         Urine, amplification test     1195   1.7             Urine: amplification test   1195   0.4      Urine, amplification test   1195   8.5
  **Region of the Americas**                                                                                                                                                                                                                                                                                          
  Huneeus et al., 2018[@R72]              Chile, Santiago                                               2012--2014           Sexually active students, ≤ 24                       Urine, amplification test     115    8.7             Urine, amplification test   115    0.0      Urine, amplification test   115    0.0
  Paredes et al., 2015[@R75]              Colombia, Sabana Centro province                              2011                 Students, 14--19                                     Urine, amplification test     536    1.1             Urine, amplification test   536    0.0      NR                          NR     NR
  **South-East Asia Region**                                                                                                                                                                                                                                                                                          
  Jatapai et al., 2013[@R148]             Thailand, national                                            Nov 2008--May 2009   Military recruits, 17--29                            Urine, amplification test     2123   7.9             Urine, amplification test   2123   0.9      NR                          NR     NR
  **European Region**                                                                                                                                                                                                                                                                                                 
  Sviben et al., 2015[@R149]              Croatia, Zagreb                                               Pre-2014             Controls in case-control study, 18--66               NR                            NR     NR              NR                          NR     NR       Urine, amplification test   200    2.0
  Ikonomidis et al., 2015[@R98]           Greece, Thessaly State                                        Feb 2012--Nov 2015   Attendees at urology and gynaecology clinic, adult   Genital, amplification test   171    0.6             NR                          NR     NR       NR                          NR     NR
  Matteelli et al., 2016[@R105]           Italy, Brescia                                                Nov 2012--Mar 2013   Sexually active students, \> 18                      Urine, amplification test     762    1.4             Urine, amplification test   762    0.0      NR                          NR     NR
  Gravningen et al., 2013[@R108]          Norway, Finnmark                                              2009                 Sexually active youth, 15--20                        Urine, amplification test     505    3.4             NR                          NR     NR       NR                          NR     NR
  Babinská et al., 2017[@R110]            Slovakia, eastern parts                                       2011                 Community members, adult                             Urine, amplification test     344    2.0             NR                          NR     NR       NR                          NR     NR
  Fernández-Benítez et al., 2013[@R111]   Spain, Laviana and Asturias                                   Nov 2010--Dec 2011   Sexually active youth, 15--24                        Urine, amplification test     210    4.3             NR                          NR     NR       NR                          NR     NR
  Field et al., 2018[@R113]               United Kingdom, national                                      Sep 2010--Aug 2012   Sexually active adults, 16--44                       NR                            NR     NR              NR                          NR     NR       Urine, amplification test   1827   0.0
  Sonnenberg et al., 2013[@R114]          United Kingdom, national                                      Sep 2010--Aug 2012   Sexually active adults, 16--44                       Urine, amplification test     1885   1.9             Urine, amplification test   1885   0.1      NR                          NR     NR
  **Eastern Mediterranean Region**                                                                                                                                                                                                                                                                                    
  Arbabi et al., 2014[@R122]              Iran (Islamic Republic of), Kashan                            Oct 2012--Aug 2013   Attendees at a public health unit, 16--60            NR                            NR     NR              NR                          NR     NR       Genital fluid, culture      233    0.9
  Yeganeh et al., 2013[@R150]             Iran (Islamic Republic of), Tehran                            Pre-2013             Urology clinic attendees, 18--50                     Urine, amplification test     100    4.0             NR                          NR     NR       NR                          NR     NR
  **Western Pacific Region**                                                                                                                                                                                                                                                                                          
  Corsenac et al., 2015[@R137]            New Caledonia, national                                       Aug--Dec 2012        Attendees at a primary health-care clinic, 18--49    Urine, amplification test     232    7.8             Urine, amplification test   232    3.4      NR                          NR     NR
  Choe et al., 2012[@R143]                Republic of Korea, Seoul                                      Mar--Dec 2010        Attendees at a health examination clinic, 20--59     Urine, amplification test     807    7.9             Urine, amplification test   807    0.6      NR                          NR     NR
  Kim et al., 2011[@R144]                 Republic of Korea, Uijeongbu                                  Jul--Dec 2010        Attendees at a check-up clinic, 20--60               Urine, amplification test     430    6.7             Urine, amplification test   430    0.5      Urine, amplification test   430    0.2

HIV: human immunodeficiency virus; NR: not reported; WHO: World Health Organization.

^a^ Tests were either nucleic acid amplification test or culture.

###### Number of data points that met the study inclusion criteria for the WHO 2016 prevalence estimates of chlamydia, gonorrhoea and trichomoniasis

  Estimation region                                                    No. of countries, territories and areas   Chlamydia            Gonorrhoea            Trichomoniasis                                                                             
  -------------------------------------------------------------------- ----------------------------------------- ----------- -------- ------------ -------- ---------------- -- -------- -------- -- -------- -------- -- -------- -------- -- ------- -------
  Central, eastern and western sub-Saharan Africa                      41                                        16          7                     2        2                   15       7           2        2           21       9           1       1
  Southern sub-Saharan Africa                                          6                                         7           4                     1        1                   6        3           1        1           6        3           1       1
  Andean, central, southern and tropical Latin America and Caribbean   42                                        25          8                     2        2                   14       6           2        2           16       5           1       1
  High-income North America                                            2                                         NA          NA                    NA       NA                  NA       NA          NA       NA          NA       NA          NA      NA
  North Africa and Middle East                                         20                                        11          4                     1        1                   5        2           0        0           5        2           1       1
  Australasia and high-income Asia Pacific                             6                                         6           2                     2        1                   4        1           2        1           3        1           1       1
  Western, central and eastern Europe and central Asia                 54                                        19          11                    6        6                   9        7           2        2           4        3           2       2
  Oceania                                                              14                                        7           3                     1        1                   7        3           1        1           5        1           0       0
  South Asia                                                           5                                         4           2                     0        0                   2        1           0        0           3        1           0       0
  East Asia and south-east Asia                                        15                                        5           2                     1        1                   2        2           1        1           6        4           0       0
  **Total**                                                            **205**                                   **100**     **43**                **16**   **15**              **64**   **32**      **11**   **10**      **69**   **29**      **7**   **7**

NA: not applicable; WHO: World Health Organization.

Note: Eight of the 112 studies with data for women had two separate data points (e.g. for different population groups).

For women, a total of 43 (21.0%) of 205 countries, territories and areas had one or more data points for chlamydia, 32 (15.6%) for gonorrhoea and 29 (14.1%) for trichomoniasis. For men, only 15 (7.3%) countries, territories and areas had one or more data points for chlamydia, 10 (4.9%) for gonorrhoea and 7 (3.4%) for trichomoniasis. For women there were sufficient data to generate summary estimates for chlamydia for the nine estimation regions, but not for gonorrhoea or trichomoniasis ([Table 4](#T4){ref-type="table"}).

###### Approach used to generate 2016 regional estimates for chlamydia, gonorrhoea and trichomoniasis

  Estimation region                                                    Women                                                                Men                                                                                                           
  -------------------------------------------------------------------- --------------------------------- ---------------------------------- -------------------------------------- -- --------------------------------- --------------------------------- ---------------------------------
  Central, eastern and western sub-Saharan Africa                      Meta-analysis                     Meta-analysis                      Meta-analysis                             Global male-to-female ratio       Global male-to-female ratio       Global male-to-female ratio
  Southern sub-Saharan Africa                                          Meta-analysis                     Meta-analysis                      Meta-analysis                             Global male-to-female ratio       Global male-to-female ratio       Global male-to-female ratio
  Andean, central, southern and tropical Latin America and Caribbean   Meta-analysis                     Meta-analysis                      Meta-analysis                             Special case^a^                   Global male-to-female ratio       Global male-to-female ratio
  High-income North America^b^                                         United States estimate for 2012   United States estimate for 2008    United States estimate for 2008           United States estimate for 2012   United States estimate for 2008   United States estimate for 2008
  North Africa and Middle East                                         Meta-analysis                     Meta-analysis                      Meta-analysis                             Global male-to-female ratio       Global male-to-female ratio       Global male-to-female ratio
  Australasia and high-income Asia Pacific                             Meta-analysis                     Gonorrhoea to chlamydia ratio      Trichomoniasis to chlamydia ratio         Global male-to-female ratio       Global male-to-female ratio       Global male-to-female ratio
  Western, central and eastern Europe and central Asia                 Meta-analysis                     Meta-analysis                      Trichomoniasis to chlamydia ratio         Meta-Analysis                     Global male-to-female ratio       Global male-to-female ratio
  Oceania                                                              Meta-analysis                     Meta-analysis                      Meta-Analysis                             Global male-to-female ratio       Global male-to-female ratio       Global male-to-female ratio
  South Asia                                                           Meta-analysis                     Gonorrhoea to chlamydia ratio      Trichomoniasis to chlamydia ratio^c^      Global male-to-female ratio       Global male-to-female ratio       Global male-to-female ratio
  East Asia and south-east Asia                                        Meta-analysis                     Gonorrhoea to chlamydia ratio^d^   Meta-analysis                             Global male-to-female ratio       Global male-to-female ratio       Global male-to-female ratio

^a^ In consultation with advisors on sexual transmitted infections for the World Health Organization (WHO) Region of the Americas, we decided to use the midpoint between the 2016 estimate generated by applying the global male-to-female ratio (7.5%) and the 2012 estimate for the region (2.1%). We deemed the former to be too high and the latter too low.

^b^ Following discussions with the United States Centers for Disease Control and Prevention, we based our estimates on the latest published United States national estimates[@R21]^,^[@R22] and assumed they remained constant over time and that estimates for 15--39-year-old people could be extrapolated to the 15--49-year age range. We did not apply the adjustments used for other Regions in the WHO estimates process. The figures for the United States were also applied to Canada.

^c^ The estimate based on the three available data points was over 4%, considerably higher than the 2012 estimate. Following discussions with regional experts we decided not to use this estimate, but instead to use the trichomoniasis to chlamydia ratio for low and lower middle-income countries, territories and areas.

^d^ This estimation region is made up of countries from East Asia and South East Asia. We used the higher and upper-middle income gonorrhoea to chlamydia ratio for East Asia and the low and lower-middle income ratio for South East Asia."

### Syphilis

As of 2 May 2018, the Spectrum-STI Database contained 1576 data points from surveys conducted since 1990, including 978 from January 2009 to December 2016.[@R151] In total, 181 (88.3%) of 205 countries, territories and areas had sufficient data to generate a Spectrum STI estimate for 2016. For the remaining 24 countries, territories and areas, we used the median value of the countries with data for the relevant WHO region as the 2016 estimate.

Prevalence and incidence estimates
----------------------------------

[Table 5](#T5){ref-type="table"} shows prevalence estimates for the WHO regions for 2016. Based on prevalence data from 2009 to 2016, the estimated pooled global prevalence of chlamydia in 15--49-year-old women was 3.8% (95% UI: 3.3--4.5) and in men 2.7% (95% UI: 1.9--3.7), with regional values ranging from 1.5 to 7.0% in women and 1.2 to 4.0% in men. For gonorrhoea, the global estimate was 0.9% (95% UI: 0.7--1.1) in women and 0.7% (95% UI: 0.5--1.1) in men, with regional values in women ranging from 0.3 to 1.9% and from 0.3 to 1.6% in men. The estimates for trichomoniasis were 5.3% (95% UI: 4.0--7.2) in women and 0.6% (95% UI: 0.4--0.9) in men, with regional values ranging from 1.6 to 11.7% in women and from 0.2 to 1.3% in men. For syphilis, the global estimate in both men and women was 0.5% (95% UI: 0.4--0.6) with regional values ranging from 0.1 to 1.6%. The WHO African Region had the highest prevalence for chlamydia in men, gonorrhoea in women and men, trichomoniasis in women and syphilis in men and women. The WHO Region of the Americas had the highest prevalence of chlamydia in women and of trichomoniasis in men.

###### Comparison of 2012 and 2016 WHO regional prevalence estimates of chlamydia, gonorrhoea, trichomoniasis and syphilis

  WHO Region, by sex             Estimated prevalence, % (95% UI)                                                                                                                                       
  ------------------------------ ---------------------------------- ---------------- -- ---------------- ---------------- -- ------------------ ------------------ -- ---------------- ---------------- ----------------
  **Women**                                                                                                                                                                                             
  African Region                 3.7 (2.7--5.2)                     5.0 (3.8--6.6)      1.7 (1.2--2.6)   1.9 (1.3--2.7)      11.5 (9.0--14.6)   11.7 (8.6--15.6)      1.8 (1.4--2.5)   1.7 (1.5--1.9)   1.6 (1.2--2.0)
  Region of the Americas         7.6 (6.7--8.7)                     7.0 (5.8--8.3)      0.8 (0.5--1.1)   0.9 (0.6--1.5)      7.7 (4.3--13.1)    7.7 (5.1--11.5)       0.4 (0.4--0.5)   0.7 (0.6--0.7)   0.9 (0.7--1.1)
  South-East Asia Region         1.8 (1.4--2.2)                     1.5 (1.0--2.5)      0.4 (0.2--0.5)   0.7 (0.4--1.2)      1.8 (1.1--2.7)     2.5 (1.3--4.9)        0.4 (0.3--0.4)   0.4 (0.2--0.5)   0.2 (0.1--0.4)
  European Region                2.2 (1.6--2.9)                     3.2 (2.5--4.2)      0.3 (0.2--0.5)   0.3 (0.1--0.6)      1.0 (0.8--1.3)     1.6 (1.1--2.3)        0.2 (0.1--0.4)   0.1 (0.1--0.1)   0.1 (0.0--0.4)
  Eastern Mediterranean Region   3.5 (2.4--5.0)                     3.8 (2.6--5.4)      0.5 (0.3--0.7)   0.7 (0.5--1.1)      5.9 (4.5--8.0)     4.7 (3.3--6.7)        0.5 (0.4--0.9)   0.6 (0.5--0.8)   0.7 (0.4--1.0)
  Western Pacific Region         6.2 (5.1--7.5)                     4.3 (3.0--5.9)      1.2 (0.8--1.7)   0.9 (0.5--1.3)      5.5 (3.3--8.9)     5.6 (2.7--10.8)       0.2 (0.2--0.3)   0.3 (0.2--0.4)   0.2 (0.1--0.4)
  Global total                   4.2 (3.7--4.7)                     3.8 (3.3--4.5)      0.8 (0.6--1.0)   0.9 (0.7--1.1)      5.0 (4.0--6.4)     5.3 (4.0--7.2)        0.4 (0.4--0.6)   0.5 (0.5--0.6)   0.5 (0.5--0.6)
  **Men**                                                                                                                                                                                               
  African Region                 2.5 (1.7--3.6)                     4.0 (2.4--6.1)      0.5 (0.3--0.9)   1.6 (0.9--2.6)      1.2 (0.7--1.7)     1.2 (0.7--1.8)        1.8 (1.1--2.8)   1.7 (1.4--2.0)   1.6 (1.2--2.0)
  Region of the Americas         1.8 (1.3--2.6)                     3.7 (2.1--5.5)      0.7 (0.4--1.0)   0.8 (0.4--1.3)      1.3 (0.9--2.0)     1.3 (0.9--1.8)        0.4 (0.3--0.6)   0.7 (0.5--0.8)   0.9 (0.7--1.2)
  South-East Asia Region         1.3 (0.9--1.8)                     1.2 (0.6--2.1)      0.5 (0.3--0.8)   0.6 (0.3--1.1)      0.2 (0.1--0.3)     0.2 (0.1--0.5)        0.4 (0.2--0.5)   0.4 (0.2--0.5)   0.2 (0.2--0.4)
  European Region                1.5 (0.9--2.6)                     2.2 (1.5--3.0)      0.3 (0.2--0.5)   0.3 (0.1--0.5)      0.1 (0.1--0.2)     0.2 (0.1--0.3)        0.2 (0.1--0.4)   0.1 (0.1--0.2)   0.1 (0.0--0.3)
  Eastern Mediterranean Region   2.7 (1.6--4.3)                     3.0 (1.7--4.8)      0.4 (0.2--0.6)   0.6 (0.3--1.0)      0.6 (0.4--0.9)     0.5 (0.3--0.7)        0.5 (0.3--0.9)   0.6 (0.5--0.8)   0.7 (0.4--1.0)
  Western Pacific Region         5.2 (3.4--7.2)                     3.4 (2.0--5.3)      1.0 (0.6--1.7)   0.7 (0.4--1.2)      0.6 (0.3--1.0)     0.6 (0.2--1.1)        0.2 (0.2--0.3)   0.3 (0.2--0.4)   0.2 (0.1--0.4)
  Global total                   2.7 (2.0--3.6)                     2.7 (1.9--3.7)      0.6 (0.4--0.9)   0.7 (0.5--1.1)      0.6 (0.4--0.8)     0.6 (0.4--0.9)        0.5 (0.3--0.7)   0.5 (0.5--0.6)   0.5 (0.4--0.6)

UI: uncertainty interval; WHO: World Health Organization.

Notes: The 2012 estimates are from Newman et al., 2015.[@R6] For syphilis both the WHO estimate for 2012 and the 2018 updated 2012 estimate using Spectrum STI are shown.[@R19] For chlamydia, gonorrhoea and trichomoniasis, the study inclusion window for 2016 was samples collected between 2009 and 2016, and for 2012, between 2005 and 2012.

These prevalence estimates correspond to the totals of 124.3 million cases of chlamydia, 30.6 million cases of gonorrhoea, 110.4 million cases of trichomoniasis and 19.9 million cases of syphilis (available from the data repository).[@R13]

Using the World Bank classification, high-income countries, territories and areas had the lowest estimated prevalence, and low-income countries, territories and areas had the highest prevalence of gonorrhoea, trichomoniasis and syphilis. For chlamydia, estimated prevalence was highest in upper-middle income countries, territories and areas ([Fig. 2](#F2){ref-type="fig"}). The SDG grouping showed the highest prevalence of all four sexually transmitted infections in Oceania region, that is, Pacific island nations excluding Australia and New Zealand (available from the data repository).[@R13]

![Prevalence estimates of chlamydia, gonorrhoea, trichomoniasis and syphilis in adults, by World Bank classification, 2016](BLT.18.228486-F2){#F2}

We estimated the global incidence rate for chlamydia in 2016 to be 34 cases per 1000 women (95% UI: 25--45) and 33 per 1000 men (95% UI: 21--48); for gonorrhoea 20 per 1000 women (95% UI: 14--28) and 26 per 1000 men (95% UI: 15--41); for trichomoniasis 40 per 1000 women (95% UI: 27--58) and 42 per 1000 men (95% UI: 23--69); and for syphilis 1.7 per 1000 women (95% UI: 1.4--2.0) and 1.6 per 1000 men (95% UI: 1.3--1.9; [Fig. 3](#F3){ref-type="fig"}). The WHO Region of the Americas had the highest incidence rate for chlamydia and syphilis in both women and men, while the WHO African Region had the highest incidence rates for gonorrhoea and trichomoniasis in women and men. Incidence rates by income category and SDG regions are available from the data repository.[@R13]

![Incidence rate estimates for chlamydia, gonorrhoea, trichomoniasis and syphilis in adults, by WHO Region, 2016](BLT.18.228486-F3){#F3}

These incidence rates translate globally into 127.2 million (95% UI: 95.1--165.9) new chlamydia cases, 86.9 million (95% UI: 58.6--123.4 million) gonorrhoea cases, 156.0 million (95% UI: 103.4--231.2 million) trichomoniasis cases and 6.3 million (95% UI: 5.5--7.1 million) syphilis cases in women and men aged 15--49 years in 2016. Together, the four infections accounted for 376.4 million new infections in 15--49-year-old people in 2016. Approximately 13.5% (50.8 million) of these infections occurred in low-income countries, territories and areas, 31.4% (118.1 million) in lower middle income, 47.1% (177.3 million) in upper-middle income and 8.0% (30.1 million) in high-income (available from the data repository).[@R13]

Comparison of estimates
-----------------------

Comparing the 2012 estimates with the estimates presented here shows that more data points were available in women for the 2016 estimates. The number increased from 69 to 100 for chlamydia, 50 to 64 for gonorrhoea and 44 to 69 for trichomoniasis. For men, the number of data points fell from 21 to 16 for chlamydia and from 12 to 11 for gonorrhoea, but increased from one to seven for trichomoniasis. The period of eligibility for both estimates was eight years with an overlap of four years (2009 to 2012); in women 27 data points were included in both estimates for chlamydia, 18 for gonorrhoea and 20 for trichomoniasis. In men, these overlaps were six, five and one, respectively.

[Table 5](#T5){ref-type="table"} compares the 2012 and 2016 prevalence estimates for the four infections. For syphilis, two estimates are presented for 2012, the published estimate[@R6] and the 2012 estimate generated using Spectrum STI and the latest Spectrum data set.[@R19] For all infections in both women and men, the 2016 global prevalence estimate was within the 95% UI for 2012. At the regional level, the 95% UIs for prevalence overlapped for all four infections in both men and women, apart from gonorrhoea in men in the WHO African Region which was higher in 2016 than in 2012.

Discussion
==========

We estimated a global total of 376.4 million new curable urogenital infections with chlamydia, gonorrhoea, trichomoniasis and syphilis in 15--49-year-old women and men in 2016. This estimate corresponds to an average of just over 1 million new infections each day. The number of individuals infected, however, is smaller as repeat infections and co-infections are common.[@R152]

The estimates of prevalence and incidence in 2016 were similar to those in 2012, both globally and by region, showing that sexually transmitted infections are persistently endemic worldwide. Grouping countries, territories and areas according to SDG regions revealed that the prevalence and incidence of all four sexually transmitted infections, in both women and men, were highest in the Oceania Region. The small island states in this SDG region are part of the WHO Western Pacific Region, which is dominated by China (owing to its population size). Therefore, the levels of sexually transmitted infections and need for infection control in these island states are masked when viewing the estimates only by WHO Region. When using the World Bank classification of countries, the prevalence of gonorrhoea, trichomoniasis and syphilis were highest in low-income countries, territories and areas. The prevalence of chlamydia was highest in the upper middle-income countries, territories and areas, partly due to high estimates in some Latin American countries. Further research is needed to determine whether these estimates reflect methodological factors or differences in *C. trachomatis* transmission.

The 2016 estimates for chlamydia, gonorrhoea and trichomoniasis were based on a systematic review of the literature complemented by outreach to experts using the same methods as in 2012. The aim was to reduce bias and insure comprehensiveness in the search for data.[@R19] For syphilis, the use of national estimates generated by a statistical model improves on the 2012 method by making use of historical trend data. The similarity between the published 2012 syphilis estimates and Spectrum STI generated estimates for 2012 provides reassurance about the validity of comparing the 2016 and 2012 estimates.

The study has limitations. First, limited prevalence data were available, despite an eight-year time window for data inclusion. Estimates for a given infection and region are therefore extrapolated from a small number of data points and ratios were used to generate estimates for some regions. For men, the lack of data was particularly striking. For syphilis, most data were from pregnant women, which might not reflect all women aged 15--49 years, or men. Second, the source studies include people in different age groups and used a range of diagnostic tests, so adjustment factors were applied to standardize measures across studies. Third, owing to the absence of empirical studies, incidence estimates were derived from the relationship between prevalence and duration of infection, and data on the average duration of infection for each of the four infections are also limited. Finally, because only studies among the general population were used, the prevalence and incidence in areas where key populations contribute disproportionately to sexually transmitted infection epidemics may have been underestimated despite the applied correction factor. These limitations have been discussed previously in detail.[@R6]

This study has implications for sexually transmitted infection programming and research. The quantity and quality of prevalence and incidence studies for sexually transmitted infections in representative samples of the general population, for both women and men, need improvement. Identifying opportunities to integrate data collection with clinical care platforms, such as HIV, adolescent, maternal, family planning and immunization is crucial. The recently developed WHO protocol for assessing the prevalence of sexually transmitted infections in antenatal care settings[@R153] provides a framework and consistent methods that can be adapted for women and men. Comparing data across studies requires better understanding of the performance characteristics of diagnostic tests, and implications for estimates of the average duration of infection for each infection. The processes for producing future prevalence estimates could be made timelier and more efficient through continually updated systematic reviews,[@R154] as well as technological solutions that automate searching of databases and facilitate high quality updates of reviews.

The global estimates of prevalence and incidence of four curable sexually transmitted infections are important in the broader global context, highlighting a continuing public health challenge. Prevalence and incidence data play an important role in the design and evaluation of programmes and interventions for sexually transmitted infections and in interpreting changes in HIV epidemiology. The global threat of antimicrobial resistance, particularly the emergence of *N. gonorrhoeae* resistance to the few remaining antimicrobials recommended for treatment, further highlights the importance of investing in monitoring prevalence and incidence.[@R155] Estimates of prevalence and incidence are essential for calculations of the burden of disease due to sexually transmitted infections, which are needed to advocate for funding to support sexually transmitted infection programmes. These burden estimates can also be used to promote innovation for point-of-care diagnostics, new therapeutics, vaccines and microbicides. The WHO Global Health Sector Strategy on Sexually Transmitted Infections sets a target of 90% reductions in the incidence of gonorrhoea and of syphilis, globally, between 2018 and 2030.[@R9] Major scale-ups of prevention, testing, treatment and partner services will be required to achieve these goals. The estimates generated in this paper, despite their limitations, provide an initial baseline for monitoring progress towards these ambitious targets.
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